$30 Billion Deal, page-1135

We are close to knowing one way or another

"The three current Phase 2 trials for HIV‐1 and
COVID‐19 are the culmination of years of careful,
stepwise, iterative, commercially focused drug
development. All activities have been undertaken
with the sole purpose of obtaining convincing
data for potential partners and international
regulatory agencies. The Company has engaged
with both of these audiences throughout the
development of the Company’s lead antiviral
drug BIT225.
Biotron has allocated considerable resources into
the development of BIT225. Development
hurdles for any first‐in‐class drug are high. But we
believe BIT225 is close to the finish line."